RioDerm 002
Alternative Names: RioDerm-002Latest Information Update: 03 Mar 2026
At a glance
- Originator RION
- Class Exosome therapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Wounds
Most Recent Events
- 12 Feb 2026 Phase-I clinical trials in Wounds in USA (Topical) prior to February 2026 (RION pipeline; February 2026)